Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Kee_Woo-sung
|
| gptkbp:country |
gptkb:South_Korea
|
| gptkbp:focusArea |
monoclonal antibodies
biosimilar development |
| gptkbp:founded |
2002
|
| gptkbp:founder |
gptkb:Seo_Jung-jin
|
| gptkbp:headquarters_location |
gptkb:Incheon,_South_Korea
|
| https://www.w3.org/2000/01/rdf-schema#label |
Celltrion
|
| gptkbp:industry |
gptkb:biotechnology
pharmaceuticals |
| gptkbp:ISIN |
KR7068270008
|
| gptkbp:listedOn |
gptkb:KOSDAQ
|
| gptkbp:marketCap |
over $20 billion (as of 2023)
|
| gptkbp:notableEvent |
First company to receive European approval for a biosimilar monoclonal antibody (Remsima)
|
| gptkbp:notableProduct |
gptkb:Herzuma
gptkb:Remsima gptkb:Truxima |
| gptkbp:numberOfEmployees |
over 2,000
|
| gptkbp:parentCompany |
gptkb:Celltrion_Group
|
| gptkbp:products |
biosimilars
biopharmaceuticals |
| gptkbp:stockExchange |
gptkb:KOSDAQ
|
| gptkbp:subsidiary |
gptkb:Celltrion_Healthcare
gptkb:Celltrion_Pharm |
| gptkbp:website |
https://www.celltrion.com
|
| gptkbp:bfsParent |
gptkb:Yeonsu_District
|
| gptkbp:bfsLayer |
6
|